# Contents

Contributors xiii  

1. Physiology of erythropoiesis  
   *U. Testa*  
   1  

2. Biology of EPO and EPO-receptor  
   *C. Lacombe and P. Mayeux*  
   67  

3. The role of erythropoietin receptor expression on tumor cells  
   *J. Fandrey*  
   81  

4. Problems associated with erythropoietin receptor determination on tumor cells  
   *A. Österborg*  
   103  

5. Definition, classification and characterization of anemia in cancer  
   *M. R. Nowrousian*  
   117  

6. Pathophysiology of anemia in cancer  
   *M. R. Nowrousian*  
   149  

7. Prevalence and incidence of anemia and risk factors for anemia in patients with cancer  
   *H. Ludwig*  
   189  

8. Significance of anemia in cancer chemotherapy  
   *M. R. Nowrousian*  
   207  

9. Incidence and impact of anemia in radiation oncology  
   *J. Dunst and M. Molls*  
   249  

10. Relationship between hemoglobin levels and tumor oxygenation  
    *P. Vaupel, A. Mayer and M. Höckel*  
    265
11. Tumor hypoxia and therapeutic resistance

*P. Vaupel and M. Höckel*

12. Symptoms of anemia

*R. Pirker*

13. Impact of anemia and red blood cell transfusion on organ function

*M. R. Nowrousian*

14. Relationship of hemoglobin, fatigue, and quality of life in anemic cancer patients

*Z. Butt and D. Cella*

15. When to use red blood cell transfusions in cancer patients with solid tumours?

*J. K. Jacob and P. J. Barrett-Lee*

16. Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin preparations

*W. Jelkmann*

17. Epoetin treatment of anemia associated with multiple myeloma and non-Hodgkin’s lymphoma

*A. Österborg*

18. rhEPO in anemic patients with solid tumors and chemotherapy – efficacy and safety

*M. R. Nowrousian*

19. Early intervention with recombinant human erythropoietin for chemotherapy-induced anemia

*G. H. Lyman and J. Glaspy*

20. Recombinant human erythropoietin (rhEPO) therapy in myelodysplasia

*E. Hellström-Lindberg*

21. Prediction of response to rhEPO in the anemia of cancer

*Y. Beguin and G. Van Straelen*

22. rhEPO in hematopoietic stem cell transplantation

*G. Van Straelen and Y. Beguin*
<table>
<thead>
<tr>
<th>Table of Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>23. Treatment of anemia with rhEPO in radiation oncology</td>
</tr>
<tr>
<td>24. Recombinant human erythropoietin in pediatric oncology</td>
</tr>
<tr>
<td>25. rhEPO in surgical oncology</td>
</tr>
<tr>
<td>26. Erythropoiesis, iron metabolism and iron supplementation during erythropoietin therapy</td>
</tr>
<tr>
<td>27. Are there risks for use of iron in cancer patients?</td>
</tr>
<tr>
<td>28. Metabolic and physiologic effects of rhEPO in anemic cancer patients</td>
</tr>
<tr>
<td>30. Thrombosis during therapy with erythropoiesis stimulating agents in cancer</td>
</tr>
<tr>
<td>31. The effect of rhEPO on survival in anemic cancer patients</td>
</tr>
<tr>
<td>32. From bench to bedside: Neuroprotective effects of erythropoietin</td>
</tr>
<tr>
<td>33. rhEPO in patients with anemia and congestive heart failure</td>
</tr>
<tr>
<td>34. Cost-effectiveness of treating cancer anaemia</td>
</tr>
<tr>
<td>Addendum</td>
</tr>
<tr>
<td>Index</td>
</tr>
</tbody>
</table>
Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology
Scientific and Clinical Aspects of Anemia in Cancer
Nowrousian, M.R. (Ed.)
2008, XVIII, 866 p., Hardcover
ISBN: 978-3-211-25223-9